Literature DB >> 8941648

Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine.

D L Kasper1, L C Paoletti, M R Wessels, H K Guttormsen, V J Carey, H J Jennings, C J Baker.   

Abstract

Group B Streptococcus (GBS) is an important perinatal pathogen. Because transplacentally acquired maternal antibodies to the GBS capsular polysaccharides (CPS) confer protection, prevention of infant disease may be possible after immunization of women. Unfortunately, the purified CPS of GBS are only variably immunogenic in adults; therefore to enhance immunogenicity we have designed and developed a CPS-protein conjugate vaccine. The lability of a conformationally dependent epitope on the III CPS containing a critical sialic acid residue was important to consider in vaccine design. 100 women were randomized to receive GBS type III CPS-tetanus toxoid conjugate (III-TT) vaccine at one of three doses; unconjugated GBS type III CPS; or saline. Serum samples were obtained before immunization and 2, 4, 8, and 26 wk thereafter, and specific antibody to type III CPS was measured. Vaccines were well tolerated. In sera from recipients of the highest dose of III-TT, CPS-specific IgG levels rose from a geometric mean of 0.09 microg/ml before immunization to 4.53 microg/ml 8 wk later, whereas levels in recipients of unconjugated type III CPS rose from 0.21 microg/ml to 1.41 microg/ml. Lower doses resulted in lower antibody levels. A > or = 4-fold rise in antibody concentration was achieved in 90% of recipients of III-TT compared with 50% of those that received III CPS (P = 0.0015). Antibodies evoked by the conjugate vaccine recognized a conformationally dependent epitope of the III-CPS, promoted opsonophagocytosis and killing of GBS, and, after maternal immunization, protected neonatal mice from lethal challenge with type III GBS. We conclude that directed coupling of type III GBS polysaccharide to a carrier protein yielded a conjugate vaccine with preserved expression of a highly labile conformational epitope involving sialic acid and enhanced immunogenicity compared with uncoupled CPS.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8941648      PMCID: PMC507681          DOI: 10.1172/JCI119042

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  26 in total

1.  Antibody affinity. 3. The role of multivalance.

Authors:  C L Hornick; F Karuch
Journal:  Immunochemistry       Date:  1972-03

2.  Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus.

Authors:  C J Baker; M A Rench; M S Edwards; R J Carpenter; B M Hays; D L Kasper
Journal:  N Engl J Med       Date:  1988-11-03       Impact factor: 91.245

Review 3.  Group B streptococcal vaccines.

Authors:  C J Baker; D L Kasper
Journal:  Rev Infect Dis       Date:  1985 Jul-Aug

4.  Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection.

Authors:  C J Baker; D L Kasper
Journal:  N Engl J Med       Date:  1976-04-01       Impact factor: 91.245

5.  Conformational aspects critical to the immunospecificity of the type III group B streptococcal polysaccharide.

Authors:  H J Jennings; C Lugowski; D L Kasper
Journal:  Biochemistry       Date:  1981-08-04       Impact factor: 3.162

6.  A model of high-affinity antibody binding to type III group B Streptococcus capsular polysaccharide.

Authors:  M R Wessels; A Muñoz; D L Kasper
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

7.  Quantitative determination of antibodies to type III group B streptococcal polysaccharide.

Authors:  H K Guttormsen; C J Baker; M S Edwards; L C Paoletti; D L Kasper
Journal:  J Infect Dis       Date:  1996-01       Impact factor: 5.226

8.  Role of antibody to native type III polysaccharide of group B Streptococcus in infant infection.

Authors:  C J Baker; M S Edwards; D L Kasper
Journal:  Pediatrics       Date:  1981-10       Impact factor: 7.124

9.  Quantitative determination of antibody to capsular polysaccharide in infection with type III strains of group B Streptococcus.

Authors:  C J Baker; D L Kasper; A Paredes; S Alpert; W M McCormack; D Goroff
Journal:  J Clin Invest       Date:  1977-05       Impact factor: 14.808

10.  Antibody recognition of the type 14 pneumococcal capsule. Evidence for a conformational epitope in a neutral polysaccharide.

Authors:  M R Wessels; D L Kasper
Journal:  J Exp Med       Date:  1989-06-01       Impact factor: 14.307

View more
  62 in total

1.  Measurement of human antibodies to type III group B Streptococcus.

Authors:  D L Kasper; M R Wessels; H K Guttormsen; L C Paoletti; M S Edwards; C J Baker
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

2.  Cognate stimulatory B-cell-T-cell interactions are critical for T-cell help recruited by glycoconjugate vaccines.

Authors:  H K Guttormsen; A H Sharpe; A K Chandraker; A K Brigtsen; M H Sayegh; D L Kasper
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

3.  Alpha C protein as a carrier for type III capsular polysaccharide and as a protective protein in group B streptococcal vaccines.

Authors:  C Gravekamp; D L Kasper; L C Paoletti; L C Madoff
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

4.  Increased sensitivity of a latex agglutination method for serotyping group B streptococcus.

Authors:  John A Elliott; Terry A Thompson; Richard R Facklam; Hans-Christian Slotved
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

5.  Localization of surface immunogenic protein on group B streptococcus.

Authors:  S Rioux; D Martin; H W Ackermann; J Dumont; J Hamel; B R Brodeur
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

Review 6.  Oxidative depolymerization of polysaccharides by reactive oxygen/nitrogen species.

Authors:  Jinyou Duan; Dennis L Kasper
Journal:  Glycobiology       Date:  2010-10-28       Impact factor: 4.313

7.  Characterization of a novel leucine-rich repeat protein antigen from group B streptococci that elicits protective immunity.

Authors:  Ravin Seepersaud; Sean B Hanniffy; Peter Mayne; Phil Sizer; Richard Le Page; Jerry M Wells
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

8.  Immunization of female mice with glycoconjugates protects their offspring against encapsulated bacteria.

Authors:  Margret Y Richter; Håvard Jakobsen; Alda Birgisdottir; Jean-François Haeuw; Ultan F Power; Giuseppe Del Giudice; Antonella Bartoloni; Ingileif Jonsdottir
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

9.  Recombinant group B streptococcus Beta C protein and a variant with the deletion of its immunoglobulin A-binding site are protective mouse maternal vaccines and effective carriers in conjugate vaccines.

Authors:  Hsiao-Hui Yang; Lawrence C Madoff; Hilde-Kari Guttormsen; Yong-Dong Liu; Lawrence C Paoletti
Journal:  Infect Immun       Date:  2007-04-30       Impact factor: 3.441

10.  Estimation of group B streptococcus type III polysaccharide-specific antibody concentrations in human sera is antigen dependent.

Authors:  R Bhushan; B F Anthony; C E Frasch
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.